Ring Transformations

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 343-362

  Morice, Christophe ^a   Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882538983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00016-0     Document Type: Chapter

References (81)

1. Schueller F.W. Chemobiodynamics and Drug Design 1960, McGraw-Hill, New York.
2. Curd F.H.S., Davey D.G., Rose F.L. Studies on synthetic antimalarial drugs-X. Some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann. Trop. Med. 1945, 39:208-214.
3. Crowther A.F., Levi A.A. Proguanyl - the isolation of a metabolite with high antimalarial activity. Br. J. Pharmacol. 1953, 8:93-101.
4. Hawking F., Perry W.L.M. Activation of paludrine. Br. J. Pharmacol. 1948, 3:320-331.
5. Weiner I.M. Drugs affecting renal function and electrolyte metabolism. Goodman and Gilman's the Pharmacological Basis of Therapeutics 1990, 708-731. Pergamon Press, New York. 8th Edition. A. Goodman-Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
6. Buzetta B., Hospital M. Relations structure-activité. Pharmacologie Moléculaire 1978, 27-36. Masson & Cie, Paris. Y. Cohen (Ed.).
7. Minutolo F., Bertini S., Papi C., Carlson K.E., Katzenellenbogen J.A., Macchia M. Salicylaldoxime moiety as a phenolic "A-Ring" substitute in estrogen receptor ligands. J. Med. Chem. 2001, 44(24):4288-4291.
8. Minutolo F., Antonello M., Bertini S., Ortore G., Placanica G., Rapposelli S., Sheng S., Carlson K.E., Katzenellenbogen B.S., Katzenellenbogen J.A., Macchia M. Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J. Med. Chem. 2003, 46(19):4032-4042.
9. Rouot B., Leclerc G., Wermuth C.G., Miesch F., Schwartz J. Synthèse et essais pharmacologiques d'arylguanidines, analogues ouverts de la clonidine. Eur. J. Med. Chem. 1978, 13:337-342.
10. Ashwood V.A., Cassidy F., Coldwell M.C., Evans J.M., Hamilton T.C., Howlett D.R., Smith D.M., Stemp G. Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans. J. Med. Chem. 1990, 33:2667-2672.
11. Mack H., Pfeiffer T., Hornberger W., Bohm H.J., Hoffken H.W. Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin. J. Enzyme Inhib. 1995, 9(1):73-86.
12. Kubinyi H. Molecular similarity. 2. The structural basis of drug design. Pharm Unserer Zeit 1998, 27(4):158-172.
13. Kaminski J.J., Wallmark B., Briving C., Andersson B.M. Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme. J. Med. Chem. 1991, 34(2):533-541.
14. Nakamura C.E., Abeles R.H. Mode of interaction of β-hydroxy-β-methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds. Biochemistry 1985, 24:1364-1376.
15. Kawai K., Tamura S., Morimoto S., Ishii H., Kuzuna S. Pharmacology of 4-benzoyl-1-indancarboxylic acid (TAI-901) and 4-(4-methylbenzoyl)-1-indancarboxylic acid (TAI-908). Arzneim.Forsch. 1982, 32:113-117.
16. Boyle E.A., Mangan F.R., Markwell R.E., Smith S.A., Thomson M.J., Ward R.W., Wyman P.A. 7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents. J. Med. Chem. 1986, 29:894-898.
17. Jenner P., Clow A., Reavill C., Theodoru A., Marsden C.D. Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms. J. Pharm. Pharmacol. 1980, 32:39-44.
18. Waterbeemd van de H., Testa B. Theoretical conformational studies of some dopamine antagonistic benzamide drugs: 3-pyrrolidyl- and 4-piperidyl derivatives. J. Med. Chem. 1983, 26:203-207.
19. Norman M.H., Kelley J.L., Hollingsworth E.B. Conformationally restricted analogues of remoxipride as potential antipsychotic agents. J. Med. Chem. 1993, 36:3417-3423.
20. Cannon J.G., Lee T., Goldman H.D., Costall B., Naylor R.J. Central dopamine agonist properties of some 2-aminotetralin derivatives after peripheral and intracerebral administration. J. Med. Chem. 1977, 20:1111-1116.
21. Seiler M.P., Bölsterli J.J., Floersheim P., Hagenbach A., Markstein R., Pfäffli P., Widmer A., Wüthrich H. Recognition at dopamine receptor subtypes. Perspectives in Medicinal Chemistry 1993, 221-237. Verlag Helvetica Chemica Acta and VCH, Basel and Weinheim. B. Testa, E. Kyburz, W. Fuhrer, R. Giger (Eds.).
22. Krogsgaard-Larsen P., Hjeds H., Falch E., Jørgensen F.S., Nielsen L. Recent advances in GABA agonists, antagonists and uptake inhibitors: structure-activity relationships and therapeutic potential. Adv. Drug Res. 1988, Vol. 17:381-456. Academic Press, London. B. Testa (Ed.).
23. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998, 138(3-4):217-230.
24. Williams M., Arneric S.P. Beyond the tobacco debate: dissecting out of the therapeutic potential of nicotine. Expert Opin. Invest. Drugs 1996, 1035-1045.
25. Glassco W., Suchocki J., George C., Martin B.R., May E.L. Synthesis, optical resolution, absolute configuration, and preliminary pharmacology of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo-[3,2-h]isoquinoline, a structural analog of nicotine. J. Med. Chem. 1993, 36:3381-3385.
26. Glennon R.A., Dukat M. Nicotine receptor ligands. Med. Chem. Res. 1996, 465-486.
27. Holladay M.W., Lebold S.A., Lin N.H. Structure-activity relationships of nicotinic acetylcholine receptor agonists as potential treatments for dementia. Drug. Dev. Res. 1995, (35):191-213.
28. Damaj M.I., Glassco W., Marks M.J., Slobe B., James J.R., May E.L., Rosecrans J.A., Collins A.C., Martin B.R. Pharmacological investigation of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo-[3,2-h]isoquinoline, a bridged-nicotine analog. J. Pharmacol. Exp. Ther. 1997, 282(3):1425-1434.
29. Ullrich T., Krich S., Binder D., Mereiter K., Anderson D.J., Meyer M.D., Pyerin M. Conformationally constrained nicotines: polycyclic, bridged, and spiro-annulated analogues as novel ligands for the nicotinic acetylcholine receptor. J. Med. Chem. 2002, 45(18):4047-4054.
30. Basil B., Coffee E.C.J., Gell D.L., Maxwell D.R., Sheffield D.J., Wooldridge K.R.H. A new class of sympathic β-receptor blocking agents. 3,4-Dihydro-3-hydroxy-1,5-benzoxazocines. J. Med. Chem. 1970, 13:403-406.
31. Evans J.M., Fake C.S., Hamilton T.C., Poyser R.H., Watts E.A. Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J. Med. Chem. 1983, 26:1582-1589.
32. Stemp G., Evans J.M. Discovery and development of cromokalim and related potassium channel activators. Med. Chem. 1993, 141-162. Academic Press, London. C.R. Ganellin, S.M. Roberts (Eds.).
33. Heel R.C., Brogden R.N., Pakes G.E., Speight T.M., Avery G.S. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1980, 19:249-267.
34. Glaser R., Donnel D. Stereoisomer differentiation for the analgesic drug nefopam hydrochloride using modeling studies of serotonin uptake area. J. Pharm. Sci. 1989, 78:87-90.
35. Antel J., Gregory P.C., Nordheim U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J. Med. Chem. 2006, 49(14):4008-4016.
36. Murineddu G., Ruiu S., Loriga G., Manca I., Lazzari P., Reali R., Pani L., Toma L., Pinna G.A. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydroben zo [6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. 2005, 48(23):7351-7362.
37. Carpino P.A., Griffith D.A., Sakya S., Dow R.L., Black S.C., Hadcock J.R., Iredale P.A., Scott D.O., Fichtner M.W., Rose C.R., Day R., Dibrino J., Butler M., Debartolo D.B., Dutcher D., Gautreau D., Lizano J.S., O'Connor R.E., Sands M.A., Kelly-Sullivan D., Ward K.M. New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorg. Med. Chem. Lett. 2006, 16(3):731-736.
38. Smith R.A., Fathi Z., Brown S.E., Choi S., Fan J., Jenkins S., Kluender H.C., Konkar A., Lavoie R., Mays R., Natoli J., O'Connor S.J., Ortiz A.A., Podlogar B., Taing C., Tomlinson S., Tritto T., Zhang Z. Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. Bioorg. Med. Chem. Lett. 2007, 17(3):673-678.
39. 3D structures were generated and minimized using DS viewerPro 6.0, © 2005, by Accelrys Software Inc.
40. Pfister, R., Sallmann, A., Hammerschmidt, W., Substituted malonic acid hydrazides. US Patent3,455,999 (July 15, 1969; Geigy Chemical Corporation).
41. Mixich G. Zum chemischen Verhalten des Antiphlogisticums "Azapropazon" (Mi 85)=3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-ben zotriazin. Helv. Chim. Acta. 1968, 51:532-538.
42. Jahn U., Wagner-Jauregg T. Vergleich von Zwei neuen Klassen Antiphlogisticher Substanzen im Collier-Test. Arzneim.-Forsch. 1968, 18:120-121.
43. Yamamoto H., Kaneko S.-I. Synthesis of 1-phenyl-2-styryl-3,5-dioxopyrazolidines as antiinflammatory agents. J. Med. Chem. 1970, 13:292-295.
44. Wermuth, C. G., Choay, J., Nouveaux dérivés de la pyrazolidine, leur procédé de fabrication et médicaments contenant ces nouveaux dérivés. Fr. Patent 2 244 513 (July 12, 1973, Choay S.A.), 1973.
45. Teger-Nilsson A.C., Bylund R., Gustafsson D., Gyzander E., Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombine inhibitor. Thromb. Res. 1997, 85:133.
46. Gustafsson D., Antonsson T., Bylund R., Eriksson U., Gyzander E., Nilsson I., Elg M., Mattson C., Deinyum J., Pehrsson S., Karlsson A., Soerensen H. Effects of melagatran, a low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemostasis 1998, 79:110.
47. Pelletier J.C., Hesson D., Jones K.A., Costa A.M. Substituted 1,2-dihydrophtalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. 1996, 39:343-346.
48. Grasso S., De Sarro G., De Sarro A., Micale N., Zappala M., Puja G., Baraldi M., De Micheli C. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphtalazin-1 (2H)-ones. J. Med. Chem. 2000, 43:2851-2859.
49. Trybulski E.J., Zhang J., Kramss R.H., Mangano R.M. The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives. J. Med. Chem. 1993, 36:3533-3541.
50. Ringdahl B., Jenden D.J. Pharmacological properties of oxotremorine and its analogues. Life Sci. 1983, 32:2401-2413.
51. Klimko P.G., Davis T.L., Griffin B.W., Sharif N.A. Synthesis and biological activity of a novel 11a-homo (cyclohexyl) prostaglandin. J. Med. Chem. 2000, 43:3400-3407.
52. Mull R.P., Maxwell R.A. Guanethidine and related adrenergic neuronal blocking agents. Antihypertensive Agents 1967, 115-149. Academic Press, New York. E. Schlittler (Ed.).
53. Giudicelli R., Najer H., Lefèvre F. Comparaison des durées d'action du N-β-guanidino-éthyl-aza-6 spiro[2,5] octane (LD 3598) et de la guanéthidine. Compt. Rend. Acad. Sci. 1965, 260:726-729.
54. Najer H., Giudicelli R., Sette J. Guanidines douées d'action anti-hypertensive, 4e mémoire: N-β-guanidinoéthyl azaspiro alcanes (1ère partie). Bull. Soc. Chim. Fr. 1964, 2572-2581.
55. Toda N., Usui H., Shimamoto K. Modification by AZ-55, guanethidine and bretylium of responses of atria and aortic strips to transmural stimulation. Jpn. J. Pharmacol. 1972, 22:125-135.
56. e mémoire: N-β-guanidinoéthyl azabicyclo alcanes. Bull. Soc. Chim. Fr. 1962, 1593-1597.
57. Anonymous, New basic derivatives of 6,9-endoxo-3-azabicyclo-[4.3.0]-nonane. Br. Patent 973,533 (February 21, 1962, Laboratoire Lumière, S.A.), 1964.
58. Anonymous, New basic derivatives of 6,9-endomethylene-3-azabicyclo-[4.3.0]-nonane. Br. Patent 972,088 (February 19, 1962, Laboratoire Lumière, S.A.), 1964.
59. Bryans J. S., Morrell, A. I., Novel stereoselective processes for preparation of gabapentin analogues W09914184 (Warner-Lambert Company (USA)), 1999.
60. Horwell, D. C., Bryans, J. S., Kneen, C. O., Morrell, A. I., Ratcliffe, G. S. Preparation of novel bridge cyclic amino acids as pharmaceutical agents W09733859 (Warner-Lambert Company (USA)), 1997.
61. Meyer M.D., Altenbach R.J., Basha F.Z., Carroll W.A., Condon S., Elmore S.W., Kerwin J.F., Sippy K.B., Tietje K., Wendt M.D., Hancock A.A., Brune M.E., Buckner S.A., Drizin I. Structure-activity studies for a novel series of tricyclic substituted hexahydrobe-nz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J. Med. Chem. 2000, 43(8):1586-1603.
62. Jongebreur G. Relation between the chemical constitution and the pharmacological action, especially on the coronary vessels of the heart, of some synthesized pyrones and khellin. Arch. Intern. Pharmacodynamie. 1952, 90:384-411.
63. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Lotti V.J., Cerino D.J., Chen T.B., Kling P.J., Kunkel K.A., Springer J.P., Hirshfield J. Methods for drug discovery: development of potent, selective, orally effective cholecystokin antagonists. J. Med. Chem. 1988, 31:2235-2246.
64. Janssen P.A.J., Van der Eycken C.A.M. The chemical anatomy of potent morphine-like analgesics. Drugs Affecting the Central Nervous system 1968, 25-60. Marcel Dekker, Inc., New York. A. Burger (Ed.).
65. Hjorth S., Carlsson A., Wikström H., Lindberg P., Sanchez D., Hacksell U., Arvidsson L.-E., Svensson U., Nilsson J.L.G. 3-PPP, a new centrally acting DA-receptor agonist with selectivity for auto-receptors. Life Sci. 1981, 28:1225-1238.
66. Bach N.J., Kornfeld E.C., Jones N.D., Chaney M.O., Dorman D.E., Paschal J.W., Clemens J.A., Smalstig E.B. Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrazoles as dopamine agonists. J. Med. Chem. 1980, 23:481-491.
67. Fuller R.W., Clemens J.A., Kornfeld E.C., Snoddy H.D., Smalstig E.B., Bach N.J. Effects of (8β)-8-[(methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci. 1979, 24:375-382.
68. Kelly T.R., Howard H.R., Koe K., Sarges R. Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of (±)-3-PPP (3-(3-hydroxyphenyl)-1-n-propylpiperidine). J. Med. Chem. 1985, 28:1368-1371.
69. Chang R.S.L., Lotti V.Y. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide CCK antagonist. Proc. Natl. Acad. Sci. USA 1986, 83:4923-4926.
70. Bock M.G., DiPardo R.M., Rittle K.E., Evans B.E., Freidinger R.M., Veber D.F., Chang R.S.L., Chen T.-B., Keegan M.E., Lotti V.J. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. J. Med. Chem. 1986, 29:1941-1945.
71. Bruderlein F.T., Humber L.G., Voith K. Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. 1. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds. J. Med. Chem. 1975, 18:185-191.
72. Imhof R., Kyburz E., Daly J.J. Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties. J. Med. Chem. 1984, 27:165-175.
73. Evans R.H., Francis A.A., Jones A.W., Smith D.A.S., Watkins J.C. The effects of a series of ω-phosphonic α-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br. J. Pharmacol. 1982, 75:65-75.
74. Hutchinson A.J., Williams M., Angst C., de Jesus R., Blanchard L., Jackson R.H., Wilusz E.J., Murphy D.E., Bernard P.S., Schneider J., Campbell T., Guida W., Sills M.A. 4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-d-aspartic acid receptors, and anticonvulsant activity. J. Med. Chem. 1989, 32:2171-2178.
75. Humblet, C., Johnson, G., Malone, T., Ortwine, D. F. In Design, synthesis and molecular modeling of phosphonoalkyl-substituted tetra-hydroisoquinolines as competitive NMDA antagonists. Proceedings of the XIth International Symposium on Medicinal Chemistry, Jerusalem, Israël, 1990, p. 26.
76. Ornstein P.L., Arnold M.B., Augenstein N.K., Lodge D., Leander J.D., Schoepp D.D. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 -carboxylic acid: a structurally novel, systematically active, competitive AMPA receptor antagonist. J. Med. Chem. 1993, 36:2046-2048.
77. Koga H., Itoh A., Murayama S., Suzue S., Irikura T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J. Med. Chem. 1980, 23:1358-1363.
78. Jinbo Y., Taguchi M., Inoue Y., Kondo H., Miyasaka T., Tsujishita H., Sakamoto F., Tsukamoto G. Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. 2. J. Med. Chem. 1993, 36:3148-3153.
79. Wijngaarde van I., Hamminga D., Hes R.v., Standaar P.J., Tipker J., Tulp M.T.M., Mol F., Olivier B., Jonge de A. Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives. 1. J. Med. Chem. 1993, 36:3693-3699.
80. Faust R., Garrat P.J., Yeh L.-K., Tsotinis A., Panoussopoulou M., Calogeropoulou T., Teh M.-T., Sugden D. Mapping the melatonin receptor. 6. Melatoonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J. Med. Chem. 2000, 43:1050-1061.
81. Stanton J.L., Sperbeck D.M., Trapani A.J., Cote D., Sakane Y., Berry C.J., Ghai R.D. Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors. J. Med. Chem. 1993, 36:3829-3833.